Objective The addition of androgen deprivation therapy (ADT) to conventional radiation
therapy improves overall survival (OS) in intermediate-and high-risk prostate cancer. The
benefit of ADT to added to dose-escalated radiotherapy is less clear. The aim of this study
was to report disease control outcomes and to identify prognostic variables associated with
favorable outcomes in patients with intermediate-and high-risk prostate cancer treated with
dose-escalated radiation therapy without ADT. Methods and materials From September …

Purpose To report the toxicity and long-term outcomes of dose-escalated intensity-
modulated radiation therapy (IMRT) for patients with localised prostate cancer. Methods and
Materials From 2001 to 2005, a total of 125 patients with histologically confirmed T1-3N0M0
prostate cancer were treated with IMRT to 74Gy at the Austin Health Radiation Oncology
Centre. The median follow-up was 5.5 years (range 0.5–8.9 years). Biochemical prostate
specific antigen (bPSA) failure was defined according to the Phoenix consensus definition …